Art

J-GLOBAL ID：200902174205453326   Reference number：96A0672065

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

Author (9)： ROTHENBERG M L (Cancer Therapy and Res. Center, TX, USA) ,  MOORE M J (Princess Margaret Hospital, Toronto, CAN) ,  CRIPPS M C (Ottawa Regional Cancer Center, Ontario, CAN) ,  ANDERSEN J S (Lilly Res. Lab., IN, USA) ,  PORTENOY R K (Memorial Sloan-Kettering Cancer Center, NY, USA) ,  BURRIS H A III (Cancer Therapy and Res. Center, TX, USA) ,  GREEN M R (Univ. California, CA, USA) ,  BROWN T D (Duke Univ. Medical Center, NC, USA) ,  VON HOFF D D (Cancer Therapy and Res. Center, TX, USA)
Material： Annals of Oncology  (Ann Oncol)
Volume： 7  Issue： 4  Page： 347-353  Publication year： Apr. 1996 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Terms in the title (2)： 5-FU ,  Cancer